Prospera Financial Services Inc Novo Nordisk A S Transaction History

Prospera Financial Services Inc

$5.55 Billion
Q3 2025

A detailed history of Prospera Financial Services Inc transactions in Novo Nordisk A S stock. As of the latest transaction made, Prospera Financial Services Inc holds 420,795 shares of NVO stock, worth $20.4 Million. This represents 0.42% of its overall portfolio holdings.

Number of Shares

420,795

Previous 378,006 11.32%

Holding current value

$20.4 Million

Previous $26.1 Million 10.5%

% of portfolio

0.42%

Previous 0.51%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 06, 2025	BUY	$45.38 - $71.7 $1.94 Million - $3.07 Million	42,789 Added 11.32%	420,795 $23.3 Million
Q2 2025 Aug 06, 2025	BUY	$58.08 - $81.05 $16 Million - $22.3 Million	275,104 Added 267.35%	378,006 $26.1 Million
Q1 2025 May 15, 2025	BUY	$69.3 - $90.95 $395,079 - $518,505	5,701 Added 5.87%	102,902 $7.15 Million
Q4 2024 Feb 13, 2025	BUY	$85.0 - $120.04 $912,135 - $1.29 Million	10,731 Added 12.41%	97,201 $8.36 Million
Q3 2024 Nov 07, 2024	BUY	$119.07 - $145.42 $1.26 Million - $1.54 Million	10,562 Added 13.91%	86,470 $10.3 Million

Q2 2024 Aug 13, 2024	SELL	$122.71 - $146.91 $239,652 - $286,915	-1,953 Reduced 2.51%	75,908 $10.8 Million
Q1 2024 Aug 13, 2024	SELL	$102.11 - $135.92 $638,187 - $849,499	-6,250 Reduced 8.23%	69,658 $8.94 Million
Q4 2023 Feb 14, 2024	BUY	$87.78 - $105.45 $248,505 - $298,528	2,831 Added 3.77%	77,861 $8.05 Million
Q3 2023 Nov 13, 2023	BUY	$90.94 - $199.54 $3.53 Million - $7.75 Million	38,850 Added 107.38%	75,030 $6.82 Million
Q2 2023 Aug 08, 2023	BUY	$155.98 - $172.65 $2.06 Million - $2.27 Million	13,176 Added 57.28%	36,180 $5.86 Million
Q1 2023 May 12, 2023	SELL	$132.34 - $159.14 $39,702 - $47,741	-300 Reduced 1.29%	23,004 $3.66 Million
Q4 2022 Feb 08, 2023	BUY	$102.55 - $135.33 $90,551 - $119,496	883 Added 3.94%	23,304 $3.15 Million
Q3 2022 Oct 27, 2022	SELL	$95.28 - $116.93 $410,942 - $504,319	-4,313 Reduced 16.13%	22,421 $2.23 Million
Q2 2022 Aug 08, 2022	BUY	$103.24 - $121.81 $129,050 - $152,262	1,250 Added 4.91%	26,734 $2.98 Million
Q1 2022 May 04, 2022	BUY	$93.1 - $112.54 $937,796 - $1.13 Million	10,073 Added 65.36%	25,484 $2.83 Million
Q4 2021 Feb 10, 2022	SELL	$95.88 - $117.08 $94,633 - $115,557	-987 Reduced 6.02%	15,411 $1.73 Million
Q3 2021 Nov 12, 2021	SELL	$84.42 - $106.62 $23,890 - $30,173	-283 Reduced 1.7%	16,398 $1.57 Million
Q2 2021 Aug 12, 2021	BUY	$67.66 - $84.76 $947 - $1,186	14 Added 0.08%	16,681 $1.4 Million
Q1 2021 May 06, 2021	BUY	$67.06 - $75.82 $144,514 - $163,392	2,155 Added 14.85%	16,667 $1.12 Million
Q4 2020 Feb 12, 2021	BUY	$63.89 - $73.8 $867,626 - $1 Million	13,580 Added 1457.08%	14,512 $1.01 Million
Q3 2020 Nov 04, 2020	SELL	$63.69 - $70.22 $830,326 - $915,458	-13,037 Reduced 93.33%	932 $65,000
Q2 2020 Aug 07, 2020	BUY	$58.54 - $67.94 $84,414 - $97,969	1,442 Added 11.51%	13,969 $915,000
Q1 2020 May 15, 2020	SELL	$49.46 - $64.78 $26,411 - $34,592	-534 Reduced 4.09%	12,527 $754,000
Q4 2019 Feb 12, 2020	BUY	$49.86 - $58.26 $195,949 - $228,961	3,930 Added 43.04%	13,061 $756,000
Q3 2019 Oct 22, 2019	SELL	$47.54 - $53.43 $139,910 - $157,244	-2,943 Reduced 24.37%	9,131 $472,000
Q2 2019 Aug 14, 2019	BUY	$46.79 - $52.47 $325,471 - $364,981	6,956 Added 135.91%	12,074 $611,000
Q2 2019 Aug 14, 2019	SELL	$46.79 - $52.47 $116,179 - $130,283	-2,483 Reduced 32.67%	5,118 $242,000
Q1 2019 May 02, 2019	BUY	$46.36 - $52.63 $115,111 - $130,680	2,483 Added 48.52%	7,601 $390,000
Q4 2018 Feb 13, 2019	BUY	$41.54 - $47.25 $212,601 - $241,825	5,118 New	5,118 $242,000

Others Institutions Holding NVO

# of Institutions

1,695

Shares Held

303M

Call Options Held

25.9M

Put Options Held

43.8M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $109B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prospera Financial Services Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prospera Financial Services Inc with notifications on news.

Account

Prospera Financial Services Inc Novo Nordisk A S Transaction History